ESTRATÉGIA DE CRONOSUPLEMENTAÇÃO / CRONOBIOLOGIA
JEJUM
CAFÉ DA
MANHÃ
KRILL VIT
(Vitafor)
2
ISOFORT
(Vitafor)
2 scoops
GLUTAMAX
(Vitafor)
LANCHE DA
MANHÃ
1 scoop
1
DEITAR
1
1
1 sachê
2
EXTEND ULTRA
(VRP)
KALAWALA
(Organic Hope)
2
1
SAMe 400 mg
(Life Extension)
1
1
NAD+ CELL
REGENERATOR
(Life Extension)
1
1
EPICOR
(Vitafor)
1
1
1
PEONY IMMUNE
(Life Extension)
PYCNOGENOL
100 mg
(Life Extension)
JANTAR
1 scoop
1
5-LOX INHIBITOR WITH
APRÈSFLEX
(Life Extension)
DHEA 100 mg
(VRP)
LANCHE DA
TARDE
2 scoops
MEGA DHA
(Vitafor)
THYMIC PROTEIN A
4 mcg
(Pro Boost)
ALMOÇO
1
1
1
1
1
1
KRILL VIT (Vitafor)
DIFERENÇA PRINCIPAL ENTRE ÓLEO DE KRILL E ÓLEO DE PEIXE NA
AUTOIMUNIDADE:
LOCAL DE AÇÃO
ÓLEOS DE PEIXE MODULAM FAVORAVELMENTE CITOCINAS
INFLAMATÓRIAS QUE CIRCULAM NO SANGUE
ÓLEO DE KRILL:
BENEFÍCIOS SÃO LOCAIS
(REDUZ INFILTRAÇÃO DE CÉLULAS INFLAMATÓRIAS NA ARTICULAÇÃO E
CARTILAGEM)
Ierna M, Kerr A, Scales H, Berge K, Griinari M. Supplementation of diet with krill oil protects against experimental
rheumatoid arthritis. BMC Musculoskelet Disord. 2010;11:136
ANULA NÍVEIS DE PROTEÍNA-C REATIVA
Deutsch L. Evaluation of the effect of Neptune Krill Oil on chronic inflammation and arthritic symptoms. J Am Coll
Nutr. 2007 Feb;26(1):39-48
Tou JC, Jaczynski J, Chen YC. Krill for human consumption: nutritional value and potential health benefits. Nutr
Rev. 2007 Feb;65(2):63-77
DIMINUI SIGNIFICATIVAMENTE A PONTUAÇÃO WOMAC
(AVALIA NÍVEIS DE DOR, INCHAÇO E PREJUÍZO FUNCIONAL)
Deutsch L. Evaluation of the effect of Neptune Krill Oil on chronic inflammation and arthritic symptoms. J Am Coll
Nutr. 2007 Feb;26(1):39-48
NA AUTOIMUNIDADE TORNA-SE OBRIGATÓRIO O USO CONJUNTO
KRILL VIT:
ALTOS NÍVEIS DE ASTAXANTINA NATURAL
REDUZ OXIDAÇÃO DO TECIDO CARTILAGINOSO
Chan KC, Mong MC, Yin MC. Antioxidative and anti-inflammatory neuroprotective effects of astaxanthin and
canthaxanthin in nerve growth factor differentiated PC12 cells. J Food Sci. 2009 Sep;74(7):H225-31.
Kim YJ, Kim YA, Yokozawa T. Protection against oxidative stress, inflammation, and apoptosis of high-glucoseexposed proximal tubular epithelial cells by astaxanthin. J Agric Food Chem. 2009 Oct 14;57(19):8793-7.
REDUZ NÍVEIS DA ENZIMA PRÓ-INFLAMATÓRA ÓXIDO NÍTRICO SINTASE
(iNOS)
Kim YJ, Kim YA, Yokozawa T. Protection against oxidative stress, inflammation, and apoptosis of high-glucoseexposed proximal tubular epithelial cells by astaxanthin. J Agric Food Chem. 2009 Oct 14;57(19):8793-7.
Choi SK, Park YS, Choi DK, Chang HI. Effects of astaxanthin on the production of NO and the expression of COX2 and iNOS in LPS-stimulated BV2 microglial cells. J Microbiol Biotechnol. 2008 Dec;18(12):1990-6.
Schmidt N, Pautz A, Art J, et al. Transcriptional and post-transcriptional regulation of iNOS expression in human
chondrocytes. Biochem Pharmacol. 2010 Mar 1;79(5):722-32.
INIBE APOPTOSE DE CÉLULAS DE CARTILAGEM PROVOCADA POR
OXIDAÇÃO
Kim JH, Choi W, Lee JH, et al. Astaxanthin inhibits H2O2-mediated apoptotic cell death in mouse neural progenitor
cells via modulation of P38 and MEK signaling pathways. J Microbiol Biotechnol. 2009 Nov;19(11):1355-63
ANULA NÍVEIS DE MMP-13 (METALOPROTEINASE DE MATRIZ 13)
ENZIMA QUE DISSOLVE CARTILAGEM
Bikadi Z, Hazai E, Zsila F, Lockwood SF. Molecular modeling of non-covalent binding of homochiral (3S,3’S)astaxanthin to matrix metalloproteinase-13 (MMP-13). Bioorg Med Chem. 2006 Aug 15;14(16):5451-8.
Kim JH, Choi W, Lee JH, et al. Astaxanthin inhibits H2O2-mediated apoptotic cell death in mouse neural progenitor
cells via modulation of P38 and MEK signaling pathways. J Microbiol Biotechnol. 2009 Nov;19(11):1355-63.
Van den Berg WB. Osteoarthritis year 2010 in review: pathomechanisms. Osteoarthritis Cartilage. 2011
Apr;19(4):338-41.
Zamli Z, Sharif M. Chondrocyte apoptosis: a cause or consequence of osteoarthritis? Int J Rheum Dis. 2011
May;14(2):159-66.
ANULA ATIVIDADE DA ENZIMA CASPASE-3 E INIBE NÍVEIS DAS CITICINAS
INFLAMATÓRIAS IL-1 /IL-6 / TNF-ALFA
Chan KC, Mong MC, Yin MC. Antioxidative and anti-inflammatory neuroprotective effects of astaxanthin and
canthaxanthin in nerve growth factor differentiated PC12 cells. J Food Sci. 2009 Sep;74(7):H225-31.
Thomas CM, Fuller CJ, Whittles CE, Sharif M. Chondrocyte death by apoptosis is associated with the initiation and
severity of articular cartilage degradation. Int J Rheum Dis. 2011 May;14(2):191-8.
SAMe (Life Extension – EUA)
(S-ADENOSIL-METIONINA)
INGREDIENTE MAIS IMPORTANTE NA LIBERTAÇÃO EMOCIONAL
ÚNICA FORMA QUÍMICA ATIVA:
DISULFATO TOSILATO
APRESENTAÇÃO:
COMPRIMIDO COM REVESTIMENTO ENTÉRICO – 200 mg / 400 mg
ISÔMERO ATIVO:
S,S
ISOMERIZAÇÃO MÍNIMA EM CADA LOTE:
91% DE ISÔMERO S,S (364 mg POR COMPRIMIDO)
ESMAGADORA MAIORIA DOS PRODUTOS DO MERCADO
(EUA – EUROPA – AUSTRÁLIA – CANADÁ):
ISÔMERO R,S (INATIVO): > 86%
MAIOR VALOR DE ISÔMERO S,S ENCONTRADO: 14%
FABRICANTE DE MATÉRIA PRIMA:
BASF
http://www.ncbi.nlm.nih.gov/pubmed/16545107
http://www.ncbi.nlm.nih.gov/pubmed/22116709
http://www.ncbi.nlm.nih.gov/pubmed/12445518
http://www.ncbi.nlm.nih.gov/pubmed/15617874
http://www.ncbi.nlm.nih.gov/pubmed/17762851
http://www.ncbi.nlm.nih.gov/pubmed/20053532
http://www.ncbi.nlm.nih.gov/pubmed/22204770
http://www.ncbi.nlm.nih.gov/pubmed/25576661
http://www.ncbi.nlm.nih.gov/pubmed/25534978
http://www.ncbi.nlm.nih.gov/pubmed/25523441
http://www.ncbi.nlm.nih.gov/pubmed/24128164
http://www.ncbi.nlm.nih.gov/pubmed/21278766
http://www.ncbi.nlm.nih.gov/pubmed/22041580
http://www.ncbi.nlm.nih.gov/pubmed/19644776
http://www.ncbi.nlm.nih.gov/pubmed/21627048
http://www.ncbi.nlm.nih.gov/pubmed/21154865
ISOFORT
DOENÇAS AUTOIMUNES SÃO AS QUE MAIS EVIDENCIAM A IMPORTÂNCIA
DA MARCA DE WHEY
NESTE CASO:
WHEY DEVE POSSUIR ALTO CONTEÚDO DE ALFA-LACTALBUMINA
ELEVA NÍVEIS CEREBRAIS DE TRIPTOFANO AO DEITAR
MELHORA >>>>>> ALERTA E MEDIDAS DE ATENÇÃO AO ACORDAR
Markus, C. R., L. M. Jonkman, J. H. C. Lammers, N. E. P. Deutz, M. H. Messer, and N. Rigtering. 2005. Evening Intake of
Alpha-Lactalbumin Increases Plasma Tryptophan Availability and Improves Morning Alertness and Brain Measures of
Attention (139kb pdf). American Journal of Clinical Nutrition 81: 1026-33.
OTIMIZA RELAÇÃO DE TRIPTOFANO COM OS OUTROS AMINOS
FORTEMENTE NEUTROS
MELHORA SIGNIFICATIVAMENTE PERFORMANCE COGNITIVA EM
MULHERES SOB FORTE STRESS
Markus, C. R., B. Olivier, and E. H. F. deHaan. 2002. Whey Protein Rich in Alpha-Lactalbumin Increases the Ratio of
Plasma Tryptophan to the Sum of the Other Large Neutral Amino Acids and Improves Cognitive Performance in StressVulnerable Subjects (86kb pdf). American Journal of Clinical Nutrition 75: 1051-6.
NESTE CASO:
ADJUVANTE DO SAMe PARA QUE A MULHER ESTEJA CONSCIENTE
DE SEU SEGUNDO MAIOR PODER
(FAZER OPÇÕES)
OTIMIZA NÍVEIS DE SEROTONINA CEREBRAL
REDUZ CORTISOL
MELHORA >>>>> HUMOR EM MULHERES VULNERÁVEIS AO STRESS
Markus, C. R., B. Olivier, G. E. M. Panhuysen, J. Van der Gugten, M. S. Alles, A. Tuiten, H. G. M. Westenberg, K. Fekkes,
H. F. Koppeschaar, and E. E. H. de Haan. 2000. The Bovine Protein a-Lactalbumin Increases the Plasma Ratio of
Tryptophan to the Other Large Neutral Amino Acids, and in Vulnerable Subjects Raises Brain Serotonin Activity, Reduces
Cortisol Concentration, and Improves Mood Under Stress (82kb pdf). American Journal of Clinical Nutrition 71: 1536-44.
FATOR CRÍTICO:
NÍVEIS DE ALFA-LACTALBUMINA PRESENTES NO ISOFORT
AMINOGRAMA DA ALFA-LACTALBUMINA PRESENTE NO ISOFORT:
PERFIL DE AMINOÁCIDOS EXPRESSO POR 100 GRAMAS DE PRODUTO OU GRAMAS SOBRE
BASE DE PROTEÍNA
ALANINA 2.0 G
ARGININA 1.3 G
ÁCIDO ASPÁRTICO 16.4 G
CISTEÍNA 4.8 G
ÁCIDO GLUTÂMICO 12.6 G
GLICINA 2.7 G
HISTIDINA 3.0 G
ISOLEUCINA 6.0 G
LEUCINA 10.8 G
LISINA 10.9 G
METIONINA 1.0 G
FENILALANINA 4.1 G
PROLINA 3.3 G
SERINA 3.4 G
TREONINA 4.9 G
TRIPTOFANO 4.9 G
TIROSINA 4.4 G
VALINA 4.5 G
KALAWALA
(Organic Hope – EUA)
(Phlebodium aureum – Polypodium leucotomos)
PLANTA:
SAMAMBAIA NATIVA DA COSTA RICA
USOS:
BRONZEADOR (PROTEGE CONTRA RAIOS DO SOL)
DERMATITE ATÓPICA – PSORÍASE – VITILIGO – MELASMA
ERUPÇÃO POLIMÓRFICA (PMLE)
FABRICANTES DE MATÉRIA PRIMA QUE DEMONSTRARAM EFICÁCIA
TERAPÊUTICA:
KALAWALA - ORGANIC HOPE (EUA)
EXTRATO PADRONIZADO EM 30% TRITERPENOS (RAIZ)
EXTRATO PADRONIZADO 45% TRITERPENOS (RIZOMA)
ENHANCED FERNBLOCK WITH RED ORANGE COMPLEX - LIFE EXTENSION (EUA)
EXTRATO PADRONIZADO EM 60% SULFOQUINOVOSILDIACILGLICERÓIS (FOLHA)
EXTRATO DE LAR
ANJA VERMELHA
INDUSTRIAL FARMACEUTICA CANTABRIA (ESPANHA)
CALAGUALA - RAIN TREE NUTRITION (EUA)
EXTRATO 50:1 (RAIZ)
CANTABRIA – HELIOCARE (EUA)
EXTRATO PADRONIZADO EM 60% SULFOQUINOVOSILDIACILGLICERÓIS (FOLHA)
PEONY IMMUNE
(Life Extension – EUA)
PLANTA:
Paeonia lactiflora
APRESENTAÇÃO:
EXTRATO PADRONIZADO EM 42% PEONIFLORINA
CÁPSULA COM 600 mg (252 mg DE INGREDIENTE ATIVO)
USOS:
REDUZ ANGIOGÊNESE NAS ARTICULAÇÕES E VASOS SANGUÍNEOS
ACELERA SURGIMENTO DE REMISSÕES
INIBE SUPERESTIMULAÇÃO DAS CÉLULAS DO REVESTIMENTO
ARTICULAR
REVERTE PREJUÍZO RENAL
REVERTE SECURA OCULAR – BUCAL – NASAL – VAGINAL (SJOGREN’S)
ÚNICO FABRICANTE DE MATÉRIA PRIMA QUE DEMONSTROU EFICÁCIA
TERAPÊUTICA:
MEDIPHARM (EUA)
PYCNOGENOL
EXTRATO DA CASCA DO PINHEIRO MARÍTIMO FRANCÊS
PADRONIZADO EM 65% PROCIANIDINAS
ÚNICO FABRICANTE DE MATÉRIA PRIMA QUE DEMONSTROU EFICÁCIA
TERAPÊUTICA:
HORPHAG RESEARCH (EUA)
http://onlinelibrary.wiley.com/doi/10.1002/ptr.915/abstract
5-LOX INHIBITOR WITH APRÈSFLEX
EXTRATO PADRONIZADO EM 20% DE ÁCIDO 3-O-ACETIL-11-CETO-Β-BOSWÉLICO
(AKBA)
ÚNICO FABRICANTE QUE DEMONSTROU EFICÁCIA TERAPÊUTICA:
PL THOMAS – LAILA NUTRA
NAD+ CELL REGENERATOR
APRESENTAÇÃO:
100 mg NICOTINAMIDA RIBOSÍDEO - NIAGEN®
CHROMADEX
(TRANS-PTEROSTILBENO – PTEROPURE)
AMPK ACTIVATOR
PLANTA:
Gynostemma pentaphyllum
Rosa canina
APRESENTAÇÃO:
EXTRATO PADRONIZADO EM 98% GYPENOSÍDEOS - ActivAMP®
GENCOR (EUA)
EXTRATO PADRONIZADO EM 5% TRANS-TILIROSIDA
NP Nutra (EUA)
REFERÊNCIAS BIBLIOGRÁFICAS
KALAWALA
PSORÍASE
Navarro-Blasco, F. J., et al. “Modification of the inflammatory activity of psoriatic arthritis in patients treated with extract of Polypodium
leucotomos (Anapsos).” Br. J. Rheumatol. 1998; 37(8): 912.
Vasange, M., et al. “A sulphonoglycolipid from the fern Polypodium decumanum and its effect on the platelet activating factor receptor in human
neutrophils.” J. Pharm. Pharmacol. 1997; 49(5): 562–617.
Vasange, M., et al. “Flavonoid constituents of two Polypodium species (Calaguala) and their effect on the elastase release in human
neutrophils.” Planta Med. 1997; 63(6): 511–17.
Vasange, M., et al. “The fern Polypodium decumanum, used in the treatment of psoriasis, and its fatty acid constituents as inhibitors of
leukotriene B4 formation.” Prostaglandins Leukotrienes Essent. Fatty Acids 1994; 50: 279–284.
Tuominen, M., et al. “Effects of calaguala and an active principle, adenosine, on platelet activating factor.” Planta Med. 1992; 58(4): 306–10.
Jimenez, D., et al. “Anapsos, an antipsoriatic drug, in atopic dermatitis.” Allergol. Immunopathol. 1987; 15(4):185–9.
Jimenez, D., et al. “Anapsos modifies immunological parameters and improves the clinical course in atopic dermatitis.” Dermatologica 1986;
173(3):154–5.
Pineiro Alvarez, B. “2 years personal experience in anapsos treatment of psoriasis in various clinical forms.” Med. Cutan. Ibero. Lat. Am. 1983;
11(1): 65–72.
Vargas, J., et al. “Anapsos, an antipsoriatic drug which increases the proportion of suppressor cells in human peripheral blood.” Ann.
Immunol. 1983; 134C(3):393–400.
Del Pino Gamboa, J., et al. “Comparative study between 120 mg. of anapsos and a placebo in 37 psoriasis patients.” Med. Cutan. Ibero. Lat.
Am. 1982; 10(3): 203–8.
Capella Perez, M. C., et al. “Double-blind study using ‘anapsos’ 120 mg. in the treatment of psoriasis.” Actas Dermosifiliogr. 1981; 72(9-10):
487-94.
Mercadal Peyri, O., et al. “Preliminary communication on the treatment of psoriasis with anapsos.” Actas Dermosifiliogr. 1981; 72(1–2): 65–8.
Padilla, H. C. “A new agent (hydrophilic fraction of Polypodium leucotomos) for management of psoriasis.” Int. J. Dermatol. 1974; 13(5): 276–
82.
REPARO CELULAR DA PELE
Reyes, E., et al. “Systemic immunomodulatory effects of Polypodium leucotomos as an adjuvant to PUVA therapy in generalized vitiligo: A pilot
study.” J. Dermatol. Sci. 2006 Jan 16;
Capote, R., et al. “Polypodium leucotomos extract inhibits trans-urocanic acid photoisomerization and photodecomposition.” J. Photochem.
Photobiol. B. 2005 Dec 30;
Middelkamp-Hup, M. A., et al. “Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin.” J. Am. Acad.
Dermatol. 2004 Dec; 51(6): 910-8.
Middelkamp-Hup, M. A., et al. “Orally administered Polypodium leucotomos extract decreases psoralen-UVA- induced phototoxicity,
pigmentation, and damage of human skin.” J. Am. Acad. Dermatol. 2004; 50(1): 41-9.
Philips, N., et al. “Predominant effects of Polypodium leucotomos on membrane integrity, lipid peroxidation, and expression of elastin and
matrixmetalloproteinase-1 in ultraviolet radiation exposed fibroblasts, and keratinocytes.” J. Dermatol. Sci. 2003 Jun; 32(1): 1-9.
Alonso-Lebrero, J. L., et al. “Photoprotective properties of a hydrophilic extract of the fern Polypodium leucotomoson human skin cells.” J.
Photochem. Photobiol. B. 2003 Apr; 70(1): 31-7.
Alcaraz, M. V., et al. “An extract of Polypodium leucotomos appears to minimize certain photoaging changes in a hairless albino mouse animal
model. A pilot study.” Photodermatol. Photoimmunol. Photomed. 1999; 15(3–4): 120–26.
Gonzalez, S., et al. “Topical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced
phototoxic reactions as well as depletion of Langerhans cells in human skin.” Photodermatol. Photoimmunol. Photomed. 1997; 13(1–2): 50–60.
Pathak, M. A., et al. “Polypodium extract as photoprotectant.” U.S. patent no. 5, 614, 197; 1997.
Gonzalez, S., et al. “Inhibition of ultraviolet-induced formation of reactive oxygen species, lipid peroxidation, erythema and skin
photosensitization by Polypodium leucotomos.” Photodermatol. Photoimmunol. Photomed. 1996; 12(2): 45
Mohammad A. “Vitiligo repigmentation with Anapsos (Polypodium leucotomos)." Int. J. Dermatol. 1989; 28(7): 479.
CÉREBRO
Alvarez, X. A., et al. “Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain
bioelectrical activity and cerebral hemodynamics." Methods Find. Exp. Clin. Pharmacol.2000; 22(7): 585–94.
Cacabelos, R., et al. “A pharmacogenomic approach to Alzheimer’s disease.” Acta Neurol. Scand. Suppl. 2000; 176: 12–19.
Alvarez, X. A., et al. “Anapsos improves learning and memory in rats with Beta-Amyloid (1-28) deposits in the hippocampus” Progress in
Alzheimer's and Parkinson’s Diseases, Ed. Fisher, A., Yoshida, M. and Hannin, I., Plenum Press, New York, 1998; pp. 699-703
Nikolov, R. “Alzheimer's disease therapy - an update.” Drug News Perspect. 1998 May; 11(4): 248-55.
Alvarez, X. A., et al. “Anapsos reverses interleukin-1 beta overexpression and behavioral deficits in nbM-lesioned rats.” Methods Find. Exp. Clin.
Pharmacol. 1997; 19(5): 299–309.
Fernandez-Novoa, L., et al. “Effects of Anapsos on the activity of the enzyme Cu-Zn-superoxide dismutase in an animal model of neuronal
degeneration.” Methods Find. Exp. Clin. Pharmacol. 1997; 19(2): 99–106.
Quintanilla A. E., et al. “Pharmaceutical composition of activity in the treatment of cognitive and/or neuroimmune dysfunctions.” U.S. patent no.
5,601,829; 1997.
INFLAMAÇÃO CRÔNICA
Punzon, C., et al. “In vitro anti-inflammatory activity of Phlebodium decumanum. Modulation of tumor necrosis factor and soluble TNF
receptors.” Int. Immunopharmacol. 2003; 3(9): 1293-9.
Manna, S. K., et al. ”Calagualine inhibits nuclear transcription factors-kappaB activated by various inflammatory and tumor promoting
agents.” Cancer Lett. 2003; 190(2): 171-82.
Navarro-Blasco, F. J., et al. “Modification of the inflammatory activity of psoriatic arthritis in patients treated with extract of Polypodium
leucotomos (Anapsos).” Br. J. Rheumatol. 1998; 37(8): 912.
MODULAÇÃO IMUNOLÓGICA
Reyes, E., et al. “Systemic immunomodulatory effects of Polypodium leucotomos as an adjuvant to PUVA therapy in generalized vitiligo: A pilot
study.” J. Dermatol. Sci. 2006 Jan 16;
Nogal-Ruiz, J. J., “Modulation by Polypodium leucotomos extract of cytokine patterns in experimental trichomoniasis model.” Parasite. 2003
Mar; 10(1): 73-8.
Sempere-Ortells, J. M., et al. “Anapsos (Polypodium leucotomos) modulates lymphoid cells and the expression of adhesion
molecules.” Pharmacol. Res. 2002; 46(2): 185–90.
Gonzalez, S., et al. “An extract of the fern Polypodium leucotomos (Difur) modulates Th1/Th2 cytokines balance in vitro and appears to exhibit
anti-angiogenic activities in vivo: Pathogenic relationships and therapeutic implications.”Anticancer Res. 2000; 20(3a): 1567–75.
Sempere-Ortells , J. M., et al. “Effect of Anapsos (Polypodium leucotomos extract) on in vitro production of cytokines.” Br. J. Clin.
Pharmacol. 1997; 43(1): 85–9.
Bernd, A., et al. “In vitro studies on the immunomodulating effects of Polypodium leucotomos extract on human leukocyte
fractions.” Arzneimittelforschung. 1995; 45(8): 901–4.
Rayward, J. et al. ”Polypodium leucotomos (PL), an herbal extract, inhibits the proliferative response of T. lymphocytes to polyclonal
mitogens.” Second Intl. Cong. on Biol. Response Modifiers, San Diego, U.S.A. 1993.
Tuominen, M., et al., “Enhancing effect of extract Polypodium leucotomos on the prevention of rejection on skin transplants” Phytotherapy
Research 1991; 5: 234–37.
INIBIÇÃO DE STRESS OXIDATIVO
Garcia, F., et al. "Phenolic components and antioxidant activity of Fernblock, an aqueous extract of the aerial parts of the fern Polypodium
leucotomos." Methods Find Exp. Clin. Pharmacol. 2006 Apr; 28(3): 157-60.
Gombau, L., et al. “Polypodium leucotomos extract: Antioxidant activity and disposition.” Toxicol. In Vitro. 2006 Jun; 20(4): 464-71.
Gomes, A. J., et al. “The antioxidant action of Polypodium leucotomos extract and Kojic acid: Reactions with reactive oxygen species.” Braz. J.
Med. Biol. Res. 2001; 34(11): 1487–94.
PUBMED
http://www.ncbi.nlm.nih.gov/pubmed?dispmax=20&pmfilter_EDatLimit=No%20Limit&cmd_current=Limits&orig_db=PubMed&cm
d=Search&term=Polypodium&doptcmdl=DocSum
REFERÊNCIAS BIBLIOGRÁFICAS
PEONY IMMUNE
http://autoimmune.pathology.jhmi.edu/faqs.cfm. Acessado Novembro 26, 2014.
Kouklakis G, Efremidou EI, Pitiakoudis M, Liratzopoulos N, Polychronidis A. Development of primary malignant melanoma
during treatment with a TNF-alpha antagonist for severe Crohn’s disease: a case report and review of the hypothetical
association between TNF-alpha blockers and cancer. Drug Des Devel Ther. 2013;7:195-9.
Raaschou P, Simard JF, Holmqvist M, Askling J. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of
malignant melanoma: nationwide population based prospective cohort study from Sweden.Bmj. 2013;346:f1939.
He DY, Dai SM. Anti-inflammatory and immunomodulatory effects of Paeonia lactiflora pall., a traditional chinese herbal
medicine. Front Pharmacol. 2011;2:10.
Wang YN, Zhang Y, Wang Y, et al. The beneficial effect of Total Glucosides of Paeony on psoriatic arthritis links to
circulating Tregs and Th1 cell function. Phytother Res. 2013 Apr 23.
http://www.altmd.com/Articles/White-Peony-Root--Encyclopedia-of-Alternative-Medi. Acessado Dezembro 19, 2014.
http://www.irjponline.com/admin/php/uploads/977_pdf.pdf. Acessado Dezembro 19, 2014.
Yang J, Wang J, Feng P, Li Y, Ma C, Xu S. Protective effect of total paeony glycoside against cerebral ischemiareperfusion injury in mice. Zhong Yao Cai. 2000 Feb;23(2):95-7.
Chang Y, Wei W, Zhang L, Xu HM. Effects and mechanisms of total glucosides of paeony on synoviocytes activities in rat
collagen-induced arthritis. J Ethnopharmacol. 2009 Jan 12;121(1):43-8.
Wu Y, Ren K, Liang C, et al. Renoprotective effect of total glucosides of paeony (TGP) and its mechanism in experimental
diabetes. J Pharmacol Sci. 2009 Jan;109(1):78-87.
Liu GL, Li YC, Shen YJ. Inhibitory effect of total glucosides of paeonia on the NF-kappaB/p65 protein expression in paws
of RA rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2010 Nov;26(11):1082-4.
Tang NY, Liu CH, Hsieh CT, Hsieh CL. The anti-inflammatory effect of paeoniflorin on cerebral infarction induced by
ischemia-reperfusion injury in Sprague-Dawley rats. Am J Chin Med. 2010;38(1):51-64.
Chang Y, Zhang L, Wang C, Jia XY, Wei W. Paeoniflorin inhibits function of synoviocytes pretreated by rIL-1alpha and
regulates EP4 receptor expression. J Ethnopharmacol. 2011 Oct 11;137(3):1275-82.
Huang D, Liu M, Yan X. Effects of total glucosides of peony on expression of inflammatory cytokines and phosphorylated
MAPK signal molecules in hippocampus induced by fibrillar Abeta42. Zhongguo Zhong Yao Za Zhi. 2011 Mar;36(6):795800.
Li J, Chen CX, Shen YH. Effects of total glucosides from paeony (Paeonia lactiflora Pall) roots on experimental
atherosclerosis in rats. J Ethnopharmacol. 2011 May 17;135(2):469-75.
Wu H, Wei W, Song L, Zhang L, Chen Y, Hu X. Paeoniflorin induced immune tolerance of mesenteric lymph node
lymphocytes via enhancing beta 2-adrenergic receptor desensitization in rats with adjuvant arthritis. Int
Immunopharmacol. 2007 May;7(5):662-73.
Chen JY, Wu HX, Chen Y, et al. Paeoniflorin inhibits proliferation of fibroblast-like synoviocytes through suppressing Gprotein-coupled receptor kinase 2. Planta medica. May 2012;78(7):665-71.
Zhang W, Dai SM. Mechanisms involved in the therapeutic effects of Paeonia lactiflora Pallas in rheumatoid
arthritis. International immunopharmacology. Sep 2012;14(1):27-31.
Zhou Z, Lin J, Huo R, et al. Total glucosides of paeony attenuated functional maturation of dendritic cells via blocking
TLR4/5 signaling in vivo. Int Immunopharmacol. 2012 Nov;14(3):275-82.
Zhu L, Wei W, Zheng YQ. Effect and mechanism of action of total glucosides of paeony on synoviocytes from rats with
collagen-induced arthritis. Yao Xue Xue Bao. 2006 Feb;41(2):166-70.
http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/ra.asp. Acessado Novembro 26, 2014.
Lin J, Xiao L, Ouyang G, et al. Total glucosides of paeony inhibits Th1/Th17 cells via decreasing dendritic cells activation
in rheumatoid arthritis. Cell Immunol. 2012 Dec;280(2):156-63.
Xu HM, Wei W, Jia XY, Chang Y, Zhang L. Effects and mechanisms of total glucosides of paeony on adjuvant arthritis in
rats.J Ethnopharmacol. 2007 Feb 12;109(3):442-8.
Wang QT, Zhang LL, Wu HX, Wei W. The expression change of beta-arrestins in fibroblast-like synoviocytes from rats
with collagen-induced arthritis and the effect of total glucosides of paeony.J Ethnopharmacol. 2011 Jan 27;133(2):511-6.
Deng H, Yan C, Xiao T, Yuan D, Xu J. Total glucosides of Paeonia lactiflora Pall inhibit vascular endothelial growth factorinduced angiogenesis. J Ethnopharmacol. 2010 Feb 17;127(3):781-5.
Du JH, Dong BD. Comparative study on clinical efficacy of using methotrexate singly or combined with total glucosides of
Paeony in treating rheumatoid arthritis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2005 Jun;25(6):540-2.
Zhao YX, Liu Y. Clinical observation on effects of leflunomid and total glucosides of paeony on rheumatoid
arthritis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2006 Apr;26(4):355-7.
Wang Y, Xing HY. Clinical observation on effect of total glucosides of paeony combined with methotrexate on rheumatoid
arthritis. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Sep;27(9):839-40.
Chen Z, Li XP, Li ZJ, Xu L, Li XM. Reduced hepatotoxicity by total glucosides of paeony in combination treatment with
leflunomide and methotrexate for patients with active rheumatoid arthritis. Int Immunopharmacol. 2013 Mar;15(3):474-7.
http://www.mayoclinic.com/health/lupus/DS00115. Acessado Novembro 27, 2014.
http://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=47. Acessado Novembro 27, 2014.
Zhang HF, Xiao WG, Hou P. Clinical study of total glucosides of paeony in patients with systemic lupus
erythematosus. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2011 Apr;31(4):476-9.
Li Z, Liu Y, Chen L, Fan X, Yang K. Clinical observation of Total Glucosides of Paeony to patients of complicated
leukopenia with systemic lupus erythematosus. China Pharmaceuticals.
Shui Z, Xu J, X L, Wei W, Xu S, Xu S. Clinical study on effect of Total Glucosides of Peony in treating systemic lupus
erythematosus as adjuvant treatment. Chinese Journal of Integrated Traditional and Western Medicine. 2003;3.
Leflunomid combined with total glucosides of paeony to treat 28 patients with systemic lupus erythematosus. Journal of
Xinxiang Medical College. 2007;24:295-8.
Liang X. The effect of Total glucosides of peony on IL-8, TNF-a and INF-a in systemic lupus erythematosus. Chinese
Journal of Modern Drug Application. 2008;2:64-66.
Zhao M, Liang GP, Tang MN, et al. Total glucosides of paeony induces regulatory CD4(+)CD25(+) T cells by increasing
Foxp3 demethylation in lupus CD4(+) T cells. Clin Immunol. 2012 May;143(2):180-7.
Zhao M, Liang G, Luo S, Lu Q. Effect of total glucosides of peony on expression and DNA methylation status of ITGAL
gene in CD4(+) T cells of systemic lupus erythematosus. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2012 May;37(5):463-8.
Ding ZX, Yang SF, Wu QF, et al. Therapeutic effect of total glucosides of paeony on lupus nephritis in MRL/lpr mice. Nan
Fang Yi Ke Da Xue Xue Bao. 2011 Apr;31(4):656-60.
Kurizky PS, Mota LM. Sexual dysfunction in patients with psoriasis and psoriatic arthritis--a systematic review. Rev Bras
Reumatol. 2012 Dec;52(6):943-8.
Yuying W, Xiaoli X, Jianwen L. Influence of total glucosides of paeony on TNF2αand IL28 in patients with psoriasis
vulgaris stationary phase. Modern Journal of Integrated Traditional Chinese and Western Medicine. 2009 June;18(18).
Fox PC. Autoimmune diseases and Sjogren’s syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci. 2007
Mar;1098:15-21.
Mostafa S, Seamon V, Azzarolo AM. Influence of sex hormones and genetic predisposition in Sjogren’s syndrome: a new
clue to the immunopathogenesis of dry eye disease. Exp Eye Res. 2012 Mar;96(1):88-97.
Jin JO, Yu Q. T Cell-Associated cytokines in the pathogenesis of Sjogren’s syndrome. J Clin Cell Immunol. 2013 Feb
26;S!(9).
Breda L, Nozzi M, De Sanctis S, Chiarelli F. Laboratory tests in the diagnosis and follow-up of pediatric rheumatic
diseases: an update. Semin Arthritis Rheum. 2010 Aug;40(1):53-72
.
Theander E, Andersson SI, Manthorpe R, Jacobsson LT. Proposed core set of outcome measures in patients with primary
Sjogren’s syndrome: 5 year follow up. J Rheumatol. 2005 Aug;32(8):1495-502.
Li CL, He J, Li ZG, Zheng LW, Hua H. Effects of total glucosides of paeony for delaying onset of Sjogren’s syndrome: An
animal study. J Craniomaxillofac Surg. 2013 Jan 18.
Zhang HF, Hou P, Xiao WG. Clinical observation on effect of total glucosides of paeony in treating patients with nonsystemic involved Sjogren syndrome. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2007 Jul;27(7):596-8.
Jing L. Clinical application of therapy of total glucosides of paeony (TGP) to Sjogren’s syndrome. China Journal of Modern
Medicine. 2006;16:78-80.
Li XM, et al. Effectiveness and safety of total glucosides of peony in the treatment of patients with Sjogren
syndrome. Anhui Medical Journal. 2006;5:370-1.
http://www.nlm.nih.gov/medlineplus/ency/article/000816.htm. Acessado Dezembro 10, 2014.
http://www.niehs.nih.gov/health/materials/autoimmune_diseases_508.pdf. Acessado Dezembro 10, 2014.
http://autoimmune.pathology.jhmi.edu/adrp.pdf. Acessado Dezembro 10, 2014.
Dejaco C, Duftner C, Grubeck-Loebenstein B, Schirmer M. Imbalance of regulatory T cells in human autoimmune
diseases. Immunology. 2006 Mar;117(3):289-300.
http://www.ncbi.nlm.nih.gov/books/NBK6453/. Acessado Dezembro 10, 2014.
http://www.niams.nih.gov/HEALTH_INFO/Autoimmune/default.asp. Acessado Dezembro 10, 2014.
Abolmaali SS, Tamaddon AM, Dinarvand R. A review of therapeutic challenges and achievements of methotrexate
delivery systems for treatment of cancer and rheumatoid arthritis. Cancer Chemother Pharmacol. 2013 May;71(5):111530.
Miller AV, Ranatunga SK. Immunotherapies in rheumatologic disorders. Med Clin North Am. 2012 May;96(3):475-96, ix-x.
Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update.BMC Med. 2013 Apr
4;11:88.
Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune
diseases. Curr Opin Rheumatol. 2013 Jan;25(1):56-64.
Zhang M, Huang S, Chen M. Immunomodulatory effect of Total Glucosides of Paeony on the patients with endogenous
uveitis. 1994.
Shen Y-x, LI X-h. Study of efect of total peony glucosides on hypergammaglobulinemia in undiferentiated connective
tissue disease. Chin J Rheumatol. 2005;9(1).
Available
at: http://my.clevelandclinic.org/disorders/connective-tissuediseases/hic_mixed_connective_tissue_disease.aspx. Acessado Dezembro 10, 2014.
Long JW, Wang YY, Pi XM, Tu YT. Clinical observation on the treatment of chronic urticaria with total glucosides of
paeony capsule combined with citirizine. Chin J Integr Med. 2010 Aug;16(4):353-6
.
Yang DQ, You LP, Song PH, Zhang LX, Bai YP. A randomized controlled trial comparing total glucosides of paeony
capsule and compound glycyrrhizin tablet for alopecia areata. Chin J Integr Med. 2012 Aug;18(8):621-5.
REFERÊNCIAS BIBLIOGRÁFICAS
NAD+ CELL REGENERATOR (Life Extension)
Shamir L, Ling SM, Scott WW Jr, et al. Knee x-ray image analysis method for automated detection of
osteoarthritis. IEEE Trans Biomed Eng. 2009 Feb;56(2):407-15.
Zhang Y, Niu J, Kelly-Hayes M, Chaisson CE, Aliabadi P, Felson DT. Prevalence of symptomatic hand
osteoarthritis and its impact on functional status among the elderly, The Framingham Study. Am J Epidemiol.
2002;156:1021-7.
Scott DL, Berry H, Capell H, et al. The long-term effects of non-steroidal anti-inflammatory drugs in osteoarthritis of
the knee: a randomized placebo-controlled trial. Rheumatology (Oxford). 2000 Oct;39(10):1095-101.
Crowley DC, Lau FC, Sharma P, et al. Safety and efficacy of undenatured type II collagen in the treatment of
osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009;6(6):312-21.
Goldring SR, Scanzello CR. Plasma proteins take their toll on the joint in osteoarthritis. Arthritis Res Ther.2012 Mar
5;14(2):111.
Deparle LA, Gupta RC, Canerdy TD, et al. Efficacy and safety of glycosylated undenatured type-II collagen (UCII®) in therapy of arthritic dogs. J Vet Pharmacol Ther. 2005 Aug;28(4):385-90.
Peal A, D’Altilio M, Simms C, et al. Therapeutic efficacy and safety of undenatured type-II collagen (UC-II®) alone
or in combination with (-)-hydroxycitric acid and chromemate in arthritic dogs. J Vet Pharmacol Ther. 2007
Jun;30(3):275-8
Gupta RC, Canerdy TD, Skaggs P, et al. Therapeutic efficacy of undenatured type-II collagen (UC-II®) in
comparison to glucosamine and chondroitin in arthritic horses. J Vet Pharmacol Ther. 2009 Dec;32(6):577-84.
Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. Effects of oral administration of type II collagen on
rheumatoid arthritis. Science. 1993 Sep 24;261(5129):1727-30.
Barnett ML, Kremer JM, St Clair EW, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a
multicenter, double-blind, placebo-controlled trial. Arthritis Rheum. 1998 Feb;41(2):290-7.
Barnett ML, Combitchi D, Trentham DE. A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid
arthritis. Arthritis Rheum. 1996 Apr;39(4):623-8.
Wei W, Zhang L-L, Xu J-H. A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type
II collagen in rheumatoid arthritis. Arthritis Research & Therapy. 2009;11:R180.
D’Altilio M, Peal A, Alvey M, et al. Therapeutic efficacy and safety of undenatured type II collagen singly or in
combination with glucosamine and chondroitin in arthritic dogs. Toxicol Mech Methods. 2007;17(4):189-96.
Gupta RC, Canerdy TD, Lindley J, et al. Comparative therapeutic efficacy and safety of type-II collagen (UC-II®),
glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate. J Anim Physiol Anim Nutr.
Epub 2011 May 30.
Bagchi D, Misner B, Bagchi M, et al. Effects of orally administered undenatured type II collagen against arthritic
inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res. 2002;22(3-4):101-10.
Heinegard D, Saxne T. The role of the cartilage matrix in osteoarthritis. Nat Rev Rheumatol. 2011 Jan;7(1):50-6.
Cohen ES, Bodmer HC. Cytotoxic T lymphocytes recognize and lyse chondrocytes under inflammatory, but not
non-inflammatory conditions. Immunology. 2003 May;109(1):8-14.
Wang Q, Rozelle AL, Lepus CM, et al. Identification of a central role for complement in osteoarthritis.Nature
Medicine. Nov 6 2011.
Adatia A, Rainsford KD, Kean WF. Osteoarthritis of the knee and hip. Part I: aetiology and pathogenesis as a basis
for pharmacotherapy. J Pharm Pharmacol. 2012 May;64(5):617-25.
Tarkowski A, Klareskog L, Carlsten H, Herberts P, Koopman WJ. Secretion of antibodies to types I and II collagen
by synovial tissue cells in patients with rheumatoid arthritis. Arthritis Rheum. 1989 Sep;32(9):1087-92.
Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial infarction with nonselective non-steroidal antiinflammatory drugs: a meta-analysis. Arthritis Res Ther. 2006;8(5):R153.
Thomas MC. Diuretics, ACE inhibitors and NSAIDs—the triple whammy. Med J Australia. Feb 2000;172(4):184-5.
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors
and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of
randomised trials. BMJ (Clinical research ed.) June 2006;332(7553):1302-8.
Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti inflammatory drugs: network
meta-analysis. BMJ (Clinical research ed.) 2011 Jan 11;342:c7086.
Rennard BO, Ertl RF, Gossman GL, Robbins RA, Rennard SI. Chicken soup inhibits neutrophil chemotaxis in
vitro. Chest. 2000 Oct;118(4):1150-7.
Gupta RC, Barnes M, Minniear J. et al. Pain reduction measured by ground force plate in arthritic dogs treated with
type-II collagen. Presented at Society of Toxicology 48th Annual Meeting, March 2009. 108(1);Abstract 769:159.
Cremer MA, Rosloniec EF, Kang AH. The cartilage collagens: a review of their structure, organization, and role in
the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med (Berl). 1998
Mar;76(3-4):275-88.
Corthay A, Backlund J, Broddefalk J, et al. Epitope glycosylation plays a critical role for T cell recognition of type II
collagen in collagen-induced arthritis. Eur J Immunol. 1998 Aug;28(8):2580-90.
Meyer O. Oral immunomodulation therapy in rheumatoid arthritis. Joint Bone Spine. 2000;67(5):384-92.
Park KS, Park MJ, Cho ML, et al. Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis
and rheumatoid arthritis. Mod Rheumatol. 2009;19(6):581-9.
Min SY, Park KS, Cho ML, et al. Antigen-induced, tolerogenic CD11c+,CD11b+ dendritic cells are abundant in
Peyer’s patches during the induction of oral tolerance to type II collagen and suppress experimental collageninduced arthritis. Arthritis Rheum. 2006 Mar;54(3):887-98.
Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today.1997
Jul;18(7):335-43.
Zhu P, Li XY, Wang HK, et al. Oral administration of type-II collagen peptide 250-270 suppresses specific cellular
and humoral immune response in collagen-induced arthritis. Clin Immunol. 2007 Jan;122(1):75-84.
Nagler-Anderson C, Bober LA, Robinson ME, Siskind GW, Thorbecke GJ. Suppression of type II collagen-induced
arthritis by intragastric administration of soluble type II collagen. Proc Natl Acad Sci U S A. 1986 Oct;83(19):74436.
Faria AM, Weiner HL. Oral tolerance. Immunol Rev. 2005;206:232-59.
http://www.cdc.gov/nchs/fastats/arthrits.htm. Acessado Abril 3, 2015.
Lanas A, Garcia-Tell G, Armada B, Oteo-Alvaro A. Prescription patterns and appropriateness of NSAID therapy
according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis.BMC
Med. 2011 Apr;14(9):38.
Egerton T. Self-reported aging-related fatigue: a concept description and its relevance to physical therapist
practice. Phys Ther. 2013 Oct;93(10):1403-13.
Busso N, Karababa M, Nobile M, et al. Pharmacological inhibition of nicotinamide
phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to
NAD.PLoS One. 2008 May 21;3(5):e2267.
Sauve AA. NAD+ and vitamin B3: from metabolism to therapies.J Pharmacol Exp Ther. 2008 Mar;324(3):88393.
Ying W. NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological
consequences. Antioxid Redox Signal. 2008 Feb;10(2):179-206.
Belenky P, Racette FG, Bogan KL, McClure JM, Smith JS, Brenner C. Nicotinamide riboside promotes Sir2
silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell. 2007 May 4;129(3):47384.
Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an
NAD-dependent histone deacetylase. Nature. 2000 Feb 17;403(6771):795-800.
Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ. Age-associated changes in oxidative
stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357.
Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Poljak A, Grant R. Age related changes in NAD+
metabolism oxidative stress and Sirt1 activity in wistar rats. PLoS One. 2011 Apr 26;6(4):e19194.
Gomes AP, Price NL, Ling AJ, et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclearmitochondrial communication during aging. Cell. 2013 Dec 19;155(7):1624-38.
Khan NA, Auranen M, Paetau I, et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside,
a vitamin B3. EMBO Mol Med. 2014 Apr 6;6(6):721-31.
Canto C, Houtkooper RH, Pirinen E, et al. The NAD(+) precursor nicotinamide riboside enhances oxidative
metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012 Jun 6;15(6):838-47.
Satoh MS, Poirier GG, Lindahl T. NAD(+)-dependent repair of damaged DNA by human cell extracts. J Biol
Chem. 1993 Mar 15;268(8):5480-7.
Anderson RM, Bitterman KJ, Wood JG, et al. Manipulation of a nuclear NAD+ salvage pathway delays aging
without altering steady-state NAD+ levels. J Biol Chem. 2002 May 24;277(21):18881-90.
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-newsArticle&ID=1936672&highlight=.
Acessado Outubro 10, 2014.
Gong B, Pan Y, Vempati P, et al. Nicotinamide riboside restores cognition through an upregulation of
proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and
mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol Aging. 2013 Jun;34(6):1581-8.
Smith CP, Thorsness PE. The molecular basis for relative physiological functionality of the ADP/ATP carrier
isoforms in Saccharomyces cerevisiae. Genetics. 2008 Jul;179(3):1285-99.
Villalba JM, Alcaín FJ. Sirtuin activators and inhibitors. Biofactors. 2012 Sep-Oct;38(5):349-59.
Landry J, Sutton A, Tafrov ST, et al. The silencing protein SIR2 and its homologs are NAD-dependent protein
deacetylases. Proc Natl Acad Sci USA. 2000 May 23;97(11):5807-11.
Imai SI, Guarente L. NAD and sirtuins in aging and disease. Trends Cell Biol. 2014 Aug;24(8):464-71.
Hirschey MD, Shimazu T, Huang JY, Schwer B, Verdin E. SIRT3 regulates mitochondrial protein acetylation
and intermediary metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:267-77.
Chen Y, Fu LL, Wen X, et al. Sirtuin-3 (SIRT3), a therapeutic target with oncogenic and tumor-suppressive
function in cancer. Cell Death Dis. 2014 Feb 6;5:e1047.
Scher MB, Vaquero A, Reinberg D. SirT3 is a nuclear NAD+-dependent histone deacetylase that translocates
to the mitochondria upon cellular stress. Genes Dev. 2007 Apr 15;21(8):920-8.
Kotas ME, Gorecki MC, Gillum MP. Sirtuin-1 is a nutrient-dependent modulator of inflammation.Adipocyte.
2013 Apr 1;2(2):113-8.
Gallí M, Van Gool F, Leo O. Sirtuins and inflammation: Friends or foes? Biochem Pharmacol. 2011 Mar
1;81(5):569-76.
Li X, Kazgan N. Mammalian sirtuins and energy metabolism. Int J Biol Sci. 2011 Feb; 7(5):575-87.
Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab. 2014
Mar;25(3):138-45.
Sebastián C , Satterstrom FK,Haigis MC, Mostoslavsky R. From sirtuin biology to human diseases: an
update. J Biol Chem. 2012 Dec 14;287(51):42444-52.
Min SW, Sohn PD, Cho SH, Swanson RA, Gan L. Sirtuins in neurodegenerative diseases: an update on
potential mechanisms. Front Aging Neurosci. 2013 Sep 25;5:53.
Sebastián C , Satterstrom FK,Haigis MC, Mostoslavsky R. From sirtuin biology to human diseases: an
update. J Biol Chem. 2012 Dec 14;287(51):42444-52.
Oellerich MF, Potente M. FOXOs and sirtuins in vascular growth, maintenance, and aging. Circ Res. 2012 Apr
27;110(9):1238-51.
Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol.
2010;5:253-95.
Kemper JK, Choi SE, Kim DH. Sirtuin 1 deacetylase: a key regulator of hepatic lipid metabolism. Vitam
Horm. 2013;91:385-404.
Tao R, Wei D, Gao H, Liu Y, DePinho RA, Dong XC. Hepatic FoxOs regulate lipid metabolism via modulation
of expression of the nicotinamide phosphoribosyltransferase gene. J Biol Chem. 2011 Apr 22;286(16):1468190.
Schug TT, Li X. Sirtuin 1 in lipid metabolism and obesity. Ann Med. 2011 May;43(3):198-211.
Ahn J, Lee H, Jung CH, Jeon TI, Ha TY. MicroRNA-146b promotes adipogenesis by suppressing the SIRT1FOXO1 cascade. EMBO Mol Med. 2013 Oct;5(10):1602-12.
Pang W, Wang Y, Wei N, et al. Sirt1 inhibits akt2-mediated porcine adipogenesis potentially by direct proteinprotein interaction. PLoS One. 2013;8(8):e71576.
Frojdo S, Durand C, Molin L, et al. Phosphoinositide 3-kinase as a novel functional target for the regulation of
the insulin signaling pathway by SIRT1. Mol Cell Endocrinol. 2011 Mar 30;335(2):166-76.
Sasaki T, Kim HJ, Kobayashi M, et al. Induction of hypothalamic Sirt1 leads to cessation of feeding via agoutirelated peptide. Endocrinology. 2010 Jun;151(6):2556-66.
Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against
diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008 Nov;8(5):347-58.
Green MF, Hirschey MD. SIRT3 weighs heavily in the metabolic balance: a new role for SIRT3 in metabolic
syndrome. J Gerontol A Biol Sci Med Sci. 2013 Feb;68(2):105-7.
Belenky P, Christensen KC, Gazzaniga F, Pletnev AA, Brenner C. Nicotinamide riboside and nicotinic acid
riboside salvage in fungi and mammals. Quantitative basis for Urh1 and purine nucleoside phosphorylase
function in NAD+ metabolism. J Biol Chem. 2009 Jan 2;284(1):158-64.
Belenky P, Stebbins R, Bogan KL, Evans CR, Brenner C. Nrt1 and Tna1-independent export of NAD+
precursor vitamins promotes NAD+ homeostasis and allows engineering of vitamin production. PLoS One.
2011 May 11;6(5):e19710.
Belenky PA, Moga TG, Brenner C. Saccharomyces cerevisiae YOR071C encodes the high affinity
nicotinamide riboside transporter Nrt1. J Biol Chem. 2008 Mar 28;283(13):8075-9.
Mouchiroud L, Houtkooper RH, Moullan N, et al. The NAD(+)/Sirtuin pathway modulates longevity through
activation of mitochondrial UPR and FOXO signaling. Cell . 2013 Jul 18;154(2):430-41.
Larson EB, Yaffe K, Langa KM. New insights into the dementia epidemic. N Engl J Med. 2013 Dec
12;369(24):2275-7.
Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s
disease. Alzheimers Dement. 2007 Jul;3(3):186-91.
Sasaki Y, Araki T, Milbrandt J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays
axonal degeneration after axotomy. J Neurosci. 2006 Aug 16;26(33):8484-91.
Tempel W, Rabeh WM, Bogan KL, et al. Nicotinamide riboside kinase structures reveal new pathways to
NAD+. PLoS Biol. 2007 Oct 2;5(10):e263.
Wolfe GI, Baker NS, Amato A, et al. Chronic cryptogenic sensory polyneuropathy: clinical and laboratory
characteristics. Arch Neurol. 1999 May;56(5):540-7.
Van Asseldonk JT, Van den Berg LH, Kalmijn S, et al. Axon loss is an important determinant of weakness in
multifocal motor neuropathy. J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):743-7.
Hanada T, Weitzer S, Mair B, et al. CLP1 links tRNA metabolism to progressive motor-neuron loss.Nature.
2013 Mar 28;495(7442):474-80.
Yang T, Chan NY, Sauve AA. Syntheses of nicotinamide riboside and derivatives: effective agents for
increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. J Med Chem. 2007 Dec
27;50(26):6458-61.
Lu SP, Kato M, Lin SJ. Assimilation of endogenous nicotinamide riboside is essential for calorie restrictionmediated life span extension in Saccharomyces cerevisiae. J Biol Chem. 2009 Jun 19;284(25):17110-9.
CRONOBIOLOGIA NA AUTOIMUNIDADE DO HOMEM DEVE INCLUIR:
MELATONIN 10 mg
(VRP - EUA)
EXPRESSA GENE VMAT2 (ESPIRITUALIDADE)
2012:
FORT DETRICK (EXÉRCITO EUA):
SUPRESSÃO DO GENE VMAT2 QUIMICAMENTE INDUZIDA
TETRABENAZINA
PRIMEIROS EXPERIMENTOS:
GUANTÁNAMO COM SUSPEITOS DE TERRORISMO
PROTOCOLO MAIS AMPLO:
VACINAÇÃO CONTRA A GRIPE EM POPULAÇÃO ISLÂMICA EM DALLAS
VETOR DA VACINA COM TETRABENAZINA
OBJETIVOS COM O SILENCIAMENTO DO GENE VMAT2:
LIMITAR A HABILIDADE DO SER HUMANO EM QUESTIONAR
COGNITIVAMENTE QUALQUER AUTORIDADE
RECONCILIAR MORAL PRÉ-ESTABELECIDA SEPARADAMENTE DE
INFLUÊNCIAS EXTERNAS
MELATONINA HIPERPURA:
EXPRESSA GENE VMAT2
Melatonin adjusts the expression pattern of clock genes in the suprachiasmatic nucleus and induces antidepressant-like effect in
a mouse model of seasonal affective disorder
http://www.ncbi.nlm.nih.gov/pubmed/25515595
Experimenting with Spirituality: Analyzing The God Gene
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2262126/